RGH-706 is under clinical development by Gedeon Richter and currently in Phase II for Prader-Willi Syndrome (PWS). According to GlobalData, Phase II drugs for Prader-Willi Syndrome (PWS) have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RGH-706’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RGH-706 is under development for the treatment of Prader-Willi syndrome. The drug candidate is administered by oral route in the form of capsule. It acts by targeting melanin-concentrating hormone receptor 1 (MCHR1).
Gedeon Richter overview
Gedeon Richter is a pharmaceutical company that develops, manufactures and markets a wide range of drugs including original, generic, and licensed products and over the counter (OTC) medicines. The company’s product portfolio consists of medicines to treat gynecological diseases, cardiovascular diseases, gastrointestinal diseases, and central nervous system disorders. Richter’s research activities focus exclusively on the development of original small molecules, recombinant biotechnology, and generic product development. It operates sales network in Hungary, Central Eastern Europe, and the Commonwealth of Independent States (CIS) countries. The company has a research and development unit in Central Eastern Europe. Gedeon Richter is headquartered in Budapest, Hungary.
For a complete picture of RGH-706’s drug-specific PTSR and LoA scores, buy the report here.